The critical role of miR-363-3p has also been reported as an inhibitor of EMT and metastatic progression in CRC, acting through direct targeting of SOX4, which highlights its potential as both a prognostic biomarker and a therapeutic candidate [73]. The gene discussed is SOX4; the disease is colorectal carcinoma.